Cvs Pharmacy # 01848 - Medicare Supplier in Belmont, MA

News Archive

Avedro to acquire Corneal Collagen Crosslinking Phase III study rights from Peschke Meditrade

Avedro, Inc. today announced it has signed a definitive agreement with Swiss-based Peschke Meditrade GmbH to acquire the rights to its Phase III studies of Corneal Collagen Crosslinking for the treatment of progressive keratoconus and post LASIK ectasia. The two randomized, controlled, multi-site clinical trials are designed to assess the safety and efficacy of riboflavin/ultraviolet-A light for halting the progression of these degenerative disorders and the accompanying decline in patient's visual acuity.

Ascepion, Debiopharm partner to develop and commercialize ASP-08126 for solid tumors

Debiopharm Group, a global biopharmaceutical development specialist that focuses on serious medical conditions and particularly oncology, and Ascepion Pharmaceuticals, Inc., a privately-held, biopharmaceutical company dedicated to the discovery and development of breakthrough small molecule drugs for the treatment of oncology and related diseases, have entered into an exclusive worldwide license agreement concerning the development and commercialization of ASP-08126 (called Debio 1144 by Debiopharm) a multikinase inhibitor currently in pre-clinical development.

ThromboGenics resubmits ocriplasmin BLA with FDA to treat symptomatic VMA

ThromboGenics NV, a biopharmaceutical company focused on developing innovative ophthalmic medicines, today announced that it has resubmitted a Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) for ocriplasmin intravitreal injection, 2.5 mg/mL, for the treatment of symptomatic Vitreomacular Adhesion (VMA) including macular hole.

Study reveals prevalence of overweight in Sweden schoolchildren

Researchers at the Sahlgrenska Academy - University of Gothenburg, Sweden - and Karolinska Institutet have carried out the first ever national study of the prevalence of overweight and obesity in schoolchildren.

Teva's acquisition of Barr cleared by FTC

Teva Pharmaceutical Industries Ltd. and Barr Pharmaceuticals, Inc. have announced that the U.S. Federal Trade Commission ("FTC") has accepted the proposed consent order in connection with the pending acquisition of Barr by Teva and granted early termination of the Hart Scott Rodino waiting period.

Read more Medical News

› Verified 6 days ago

• Blood Glucose Monitors & Supplies: Mail Order
• Blood Glucose Monitors & Supplies: Non-Mail Order
• Canes & Crutches
• Commodes, Urinals, & Bedpans
• Enteral Equipment and/or Supplies
• Enteral Nutrients
• Heat & Cold Applications
• Nebulizer Equipment & Supplies
• Ostomy Supplies
• Parenteral Equipment and/or Supplies
• Parenteral Nutrients
• Surgical Dressings
• Urological Supplies
• Walkers

News Archive

Avedro to acquire Corneal Collagen Crosslinking Phase III study rights from Peschke Meditrade

Avedro, Inc. today announced it has signed a definitive agreement with Swiss-based Peschke Meditrade GmbH to acquire the rights to its Phase III studies of Corneal Collagen Crosslinking for the treatment of progressive keratoconus and post LASIK ectasia. The two randomized, controlled, multi-site clinical trials are designed to assess the safety and efficacy of riboflavin/ultraviolet-A light for halting the progression of these degenerative disorders and the accompanying decline in patient's visual acuity.

Ascepion, Debiopharm partner to develop and commercialize ASP-08126 for solid tumors

Debiopharm Group, a global biopharmaceutical development specialist that focuses on serious medical conditions and particularly oncology, and Ascepion Pharmaceuticals, Inc., a privately-held, biopharmaceutical company dedicated to the discovery and development of breakthrough small molecule drugs for the treatment of oncology and related diseases, have entered into an exclusive worldwide license agreement concerning the development and commercialization of ASP-08126 (called Debio 1144 by Debiopharm) a multikinase inhibitor currently in pre-clinical development.

ThromboGenics resubmits ocriplasmin BLA with FDA to treat symptomatic VMA

ThromboGenics NV, a biopharmaceutical company focused on developing innovative ophthalmic medicines, today announced that it has resubmitted a Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) for ocriplasmin intravitreal injection, 2.5 mg/mL, for the treatment of symptomatic Vitreomacular Adhesion (VMA) including macular hole.

Study reveals prevalence of overweight in Sweden schoolchildren

Researchers at the Sahlgrenska Academy - University of Gothenburg, Sweden - and Karolinska Institutet have carried out the first ever national study of the prevalence of overweight and obesity in schoolchildren.

Teva's acquisition of Barr cleared by FTC

Teva Pharmaceutical Industries Ltd. and Barr Pharmaceuticals, Inc. have announced that the U.S. Federal Trade Commission ("FTC") has accepted the proposed consent order in connection with the pending acquisition of Barr by Teva and granted early termination of the Hart Scott Rodino waiting period.

Read more Medical News

› Verified 6 days ago

Suppliers in Belmont, MA

Medicare Suppliers

Durable Medical Equipment & Medical Supplies

Community/Retail Pharmacy

Prosthetic/Orthotic Supplier